trial

Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients

NCTId NCT02307396
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 21 (actual)
Sponsored by Technical University of Munich
Primary completion 2016-06-22
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
21 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2015-02-01
Primary completion
2016-06-22
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
OlanzapineAmisulprideRisperidoneHaloperidolQuetiapinePerphenazineSulpiridebromperidolZuclopenthixolThioridazinePaliperidoneZiprasidoneBenperidolFluspirilenePimozidePerazineFluphenazineFlupentixolSertindole

Sponsors

Technical University of MunichLead Sponsor

Investigators

2
Stefan Leucht, ProfessorPrincipal Investigator
Markus Dold, MDPrincipal Investigator

Sites

1 total
Munich, Germany

Facts & assertions

4 sourced
Enrollment
21
Phase
PHASE4
Primary Completion Date
2016-06-22
Status
COMPLETED
relationships
The graph out of here
drug
Olanzapine
drug
Amisulpride
drug
Risperidone
drug
Haloperidol
drug
Quetiapine
drug
Perphenazine
drug
Sulpiride
drug
bromperidol
drug
Zuclopenthixol
drug
Thioridazine
drug
Paliperidone
drug
Ziprasidone
drug
Benperidol
drug
Fluspirilene
drug
Pimozide
drug
Perazine
drug
Fluphenazine
drug
Flupentixol
drug
Sertindole
drug
lead_sponsor
Technical University of Munich
company
indication
Schizophrenia Spectrum and Other Psychotic Disorders
indication
Psychotic Disorders
indication
Schizophrenia
indication
investigator
Stefan Leucht, Professor
person
Markus Dold, MD
person